Collegium Pharmaceutical (NASDAQ:COLL) Cut to Buy at Wall Street Zen

Wall Street Zen lowered shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a report issued on Saturday morning.

A number of other analysts also recently commented on COLL. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Zacks Research upgraded Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $57.50.

Collegium Pharmaceutical Price Performance

NASDAQ COLL opened at $35.52 on Friday. Collegium Pharmaceutical has a 12 month low of $29.19 and a 12 month high of $50.79. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. The firm has a market capitalization of $1.15 billion, a PE ratio of 17.41 and a beta of 0.73. The company’s 50 day simple moving average is $34.69 and its 200 day simple moving average is $37.81.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.52 by $0.24. The firm had revenue of $193.52 million for the quarter, compared to analysts’ expectations of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.49 earnings per share. As a group, equities research analysts forecast that Collegium Pharmaceutical will post 6.76 EPS for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently bought and sold shares of the stock. Group One Trading LLC acquired a new stake in Collegium Pharmaceutical during the 4th quarter worth about $28,000. Caitong International Asset Management Co. Ltd increased its position in shares of Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 427 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Collegium Pharmaceutical by 42.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 418 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in shares of Collegium Pharmaceutical in the 4th quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Collegium Pharmaceutical by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 318 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.